EP2909201
ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR
:
EP einkaleyfi: Þýðing ekki lögð inn:
21.10.2013:
22.2.2017:
13785389.1
:
20.10.2033
:
ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR
21.10.2013
22.2.2017
:
AbbVie Deutschland GmbH & Co. KG:
Mainzer Strasse 81, 65189, Wiesbaden, DE
:
AbbVie Inc.:
1 North Waukegan Road, 60064, North Chicago, IL, US
:
HAUPT, Andreas:
Ludwigshafen, DE
:
DINGES, Jürgen:
North Chicago, Illinois, US
:
UNGER, Liliane:
Ludwigshafen, DE
:
WICKE, Karsten:
Ludwigshafen, DE
:
VAN WATERSCHOOT, Robert:
Riehen, CH
:
MITTELSTADT, Scott:
North Chicago, Illinois, US
:
DRESCHER, Karla:
Ludwigshafen, DE
:
RELO, Ana:
Ludwigshafen, DE
:
201261716824 P:
22.10.2012:
US
:
201361777114 P:
12.3.2013:
US
:
EP2013071947:
21.10.2013
:
C07D 405/14, C07D 403/04, C07D 405/04, C07D 239/42, A61K 31/506, A61P 25/00